Our studies indicate that the deletion of PTPN2 in T cells or the administration of Compound 182 similarly recruits TILs and promotes T cell activation in immunogenic AT3-OVA tumors to repress tumor growth. The gene discussed is PTPN2; the disease is neoplasm.